ArticleJournal of clinical immunology2006
Immune tolerance to cardiac myosin induced by anti-CD4 monoclonal antibody in autoimmune myocarditis rats.
Article in Journal of clinical immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 13 citations in OpenAlex.
- Review
- Mononuclear cell secretome protects from experimental autoimmune myocarditis.European heart journal · 2015Article
- Advances in monoclonal antibody application in myocarditis.Journal of Zhejiang University. Science. B · 2013Review
- The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease.Clinical reviews in allergy & immunology · 2013Review
- Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats.American journal of physiology. Heart and circulatory physiology · 2012Article
- Autoimmunological features in inflammatory cardiomyopathy.Clinical research in cardiology : official journal of the German Cardiac Society · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune myocarditis is a T-cell-mediated autoimmune disease. CD4-positive T cells are believed to be the most important for the initiation and mediation of the disease. This study was aimed at evaluating whether anti-CD4 monoclonal antibody could induce immune tolerance to porcine cardiac myosin and whether the immune tolerance could protect rats with autoimmune myocarditis from myocardial injury. Lewis rats were immunized with porcine cardiac myosin to induce experimental autoimmune myocarditis. Immune tolerance was induced by injections of anti-CD4 monoclonal antibody on days -2, -1, 0, and 1. Results showed that cardiac function of antibody-treated rats was significantly increased compared with untreated rats 18 days postimmunization examined by transthoracic echocardiography. Typical cardiac histopathological changes were observed obviously in untreated group but not in antibody-treated group. Lymphocytes obtained from antibody-treated group had no proliferative response to porcine cardiac myosin examined by lymphocyte proliferation assay. Serological examination showed that rats immunized with cardiac myosin could produce high levels of anti-cardiac myosin antibody. The administration of anti-CD4 monoclonal antibody significantly prevented the increase of them. Serum levels of Th1 cytokines were significantly down-regulated by antibody administration, while the production of Th2 cytokines were up-regulated or unaffected evaluated by enzyme-linked immunosorbent assay. It concluded that immune tolerance to porcine cardiac myosin could be induced by anti-CD4 monoclonal antibody in vivo, and cardiac dysfunction and myocardial injury could be prevented by induction of immune tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.